Blood Podcast

In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML). See the full How I Treat series on Acute Myeloid Leukemia in volume 145 issue 12 of Blood journal.

In this week's episode, we’ll learn more about the effects of daratumumab maintenance on minimal residual disease in patients with newly diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in the pathophysiology of myeloproliferative neoplasms; and a genome-wide association study that identified novel genetic loci associated with the risk of heavy menstrual bleeding.Featured ArticlesDaratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease resultsDefective neutrophil clearance in JAK2^V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24Genome-wide meta-analysis of heavy menstrual bleeding reveals 36 risk loci

Discover groundbreaking research on hematopoietic stem cells that enhances transplant success. Learn how ruxolitinib is transforming treatment for refractory macrophage activation syndrome. Explore fascinating trials that assess magrolimab’s role in acute myeloid leukemia, revealing unexpected challenges in efficacy and safety. This episode dives into innovative therapies and the pivotal role of neutrophils in improving patient outcomes, showcasing the latest advancements in transplant biology and hematological treatments.

Discover a new JAK inhibitor showing promise in reducing complications from CAR T-cell therapy, with a focus on preventing cytokine release syndrome and neurotoxicity. Dive into a fascinating study revealing how interactions between a popular vaccine and platelets might lead to post-vaccination arterial thrombosis. Lastly, learn about the alarming phenomenon of lineage switch in leukemia relapses, which poses serious challenges after immunotherapy, underscoring the urgent need for innovative detection and treatment methods.

Discover the latest in hematological treatments, including the promising combination of ruxolitinib and dexamethasone for hemophagocytic lymphohistiocytosis. Delve into innovative lysine-specific demethylase-1 inhibitors that show potential for treating sickle cell disease. The discussion also covers the complexities of low von Willebrand factor levels, highlighting clinical implications and the necessity for personalized treatment approaches.

In this episode, Associate Editor Dr. Philippe Armand discusses the Review Series on mantle cell lymphoma with author Dr. Christine Ryan. Both were authors of "Frontline management of mantle cell lymphoma", and discuss shifts in treatments and new research.Find the full review series in Volume 145 Issue 7 of Blood: "Review series on mantle cell lymphoma: sands shifting in the darkness"

Discover groundbreaking rapid assays that enhance the diagnosis of thrombotic thrombocytopenic purpura, minimizing unnecessary treatments. Learn about a powerful combination therapy using CD38 and PD-1 blockade, showing impressive outcomes in relapsed NK/T-cell lymphoma. Dive into a captivating tale of a ‘zombie enzyme’ in CREBBP-mutant lymphomas, and uncover how a bispecific antibody cleverly restores CD40 signaling to help achieve lymphoma cell death.

Discover the groundbreaking mouse model mimicking human sickle cell SC disease, providing insights into treatment possibilities. Explore the promising results of a quadruplet therapy for multiple myeloma, combining isatuximab and others. Unearth the connection between splicing factor mutations and the clonal dynamics of myelodysplastic syndromes, revealing new potential therapeutic approaches. This week’s discussions dive deep into innovative therapies reshaping hematological disease management.

Discover how AI is revolutionizing transplant risk assessment in myelofibrosis, identifying patients with poor outcomes. Explore a feasibility study on preventing priapism in men with sickle cell anemia, showcasing promising adherence to new therapies. Finally, delve into groundbreaking findings that reveal the absence of T-cell exhaustion in newly diagnosed multiple myeloma, challenging existing beliefs and opening doors for innovative treatment strategies.

Discover how social factors like income and education impact access to critical treatments for acute myeloid leukemia. Dive into groundbreaking advances in ex vivo gene therapy aimed at inherited blood disorders. Learn about the significance of inflammatory biomarkers, particularly the soluble oncostatin M receptor, in predicting patient survival rates. The discussion emphasizes the need for improved support systems and innovative therapies to enhance outcomes for those affected by these conditions.